Denali Therapeutics Inc. (DNLI) Market Cap & Valuation Ratios
Denali Therapeutics Inc. (DNLI) has a market cap of $2.9B and a price-to-sales ratio of 816.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DNLIDenali Therapeutics Inc.Follow DNLI — free
—
Price chart with a free account
- Market cap
- 2.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| DNLI | 2.9 | — | 619.4 | — | -14.9% | — | — | -71% |
| ACAD | 3.4 | 8.8 | 2.1 | 25.1 | 4.3% | +12% | 8% | 9% |
| IDYA | 3.3 | — | 10.8 | — | -3.4% | +3024% | -93% | -24% |
| CELC | 3.2 | — | — | — | -6.0% | — | — | — |
| ELVN | 3.0 | — | — | — | -2.2% | — | — | -22% |
| TARS | 3.0 | — | 4.3 | — | 1.9% | +105% | -8% | -19% |
| DYN | 2.9 | — | — | — | — | — | — | -262% |
| IRON | 2.9 | — | — | — | -6.9% | — | — | -48% |
| VKTX | 2.8 | — | — | — | -14.7% | — | — | -107% |
| NRIX | 2.8 | 10.0 | 2.9 | 6.9 | 13.4% | +739% | 41% | 102% |
| VRDN | 2.5 | — | 26.8 | — | -13.2% | — | — | -48% |
| Median of these 10 | 9.4 | 4.3 | 16.0 | -3.4% | +422% | -0.2% | -24% |
; EV/Sales 619.4 vs. 4.3.
Growth vs. price
each dot a company · hover or tap for valuesDenali Therapeutics Inc. — questions
- What is Denali Therapeutics Inc.'s market cap?
- $2.9B.
- What is Denali Therapeutics Inc.'s price-to-sales ratio?
- 816.5.
Every figure on this page comes from Denali Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.